Literature DB >> 22941841

[Diagnosis and treatment of mixed dementia].

Haruo Hanyu1.   

Abstract

Vascular dementia (VaD)--secondary to cerebrovascular disease (CVD)--has been traditionally distinguished from Alzheimer's disease (AD), which is a purely neurodegenerative form of dementia. However, CVDs such as lacunes and white matter lesions are common in patients with AD, whereas certain pathological changes of AD, including senile plaques and tangles, are observed in elderly patients with VaD. These findings indicate that mixed vascular-degenerative dementia (MD) is the most common cause of dementia in the elderly. In the treatment and prevention of dementia, the accurate diagnosis of each individual type of dementia is vital. However, recognizing the distinction between these diseases can be difficult in clinical practice. This article provides an overview of MD, including the incidence, diagnosis, and treatment. In particular, we emphasize that functional brain imaging, including perfusion single photon emission computed tomography and benzodiazepine receptor binding measurement, in combination with morphological imaging (such as magnetic resonance imaging) is useful for distinguishing AD, VaD and MD. In addition to antiplatelet medications, cholinesterase inhibitors and N-methyl-D-aspartic acid antagonists may be effective in treating MD. Moreover the vascular risk factors also should be treated appropriately. The article describes the need for further studies to develop a better understanding of MD.

Entities:  

Mesh:

Year:  2012        PMID: 22941841

Source DB:  PubMed          Journal:  Brain Nerve        ISSN: 1881-6096


  2 in total

1.  Mixed dementia: A review of the evidence.

Authors:  Nilton Custodio; Rosa Montesinos; David Lira; Eder Herrera-Pérez; Yadira Bardales; Lucía Valeriano-Lorenzo
Journal:  Dement Neuropsychol       Date:  2017 Oct-Dec

Review 2.  Vascular Dementia and Underlying Sex Differences.

Authors:  Firoz Akhter; Alicia Persaud; Younis Zaokari; Zhen Zhao; Donghui Zhu
Journal:  Front Aging Neurosci       Date:  2021-09-08       Impact factor: 5.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.